Inflammatory breast cancer: The road to progress

Oncology

Volumn 25, Issue 3, 2011, Pages

  Chung, Cathie T ^a   Martino, Silvana ^a  

^a Angeles Clinic and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RAS PROTEIN; UVOMORULIN;

CANCER REGISTRY; DISEASE MARKER; HUMAN; INFLAMMATORY BREAST CANCER; LYMPH NODE DISSECTION; MASTECTOMY; MOLECULAR DIAGNOSIS; NOTE; RARE DISEASE; SKIN BIOPSY; TUMOR MICROENVIRONMENT;

EID: 79953112048     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. National Compehensive Cancer Network Breast Cancer Guidelines, version 2.2011. Available at http://www.nccn.org/professionals/physician-gls/pdf/breast. pdf. Accessed Feb 7, 2011.
2. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60:351-75.
3. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2010. (Epub ahead of print)
4. Taylor SH, Walters R, Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer. 2010;116(11 suppl):2745-7.
5. Yamauchi H, Cristofanilli M, Nakamura S, et al. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol. 2009;6:387-94.
6. Wu M, Wu Z-F, Rosenthal DT, et al. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer. 2010;116(11 suppl):2768-82.
7. Ye Y, Tellez JD, Durazo M, et al. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking. Anticancer Res. 2010;30:3903-10.
8. Van Laere S, Van der Auwera I, Van den Eynden G, et al. Distinct molecular phenotype compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer. 2007;97:1165-74. (Pubitemid 47586999)
9. Sinclair S, Swain SM. Primary systemic chemotherapy for inflammatory breast cancer. Cancer. 2010;116(11 suppl):2821-8.
10. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009;10:581-8.